CYTEK BIOSCIENCES, INC. Increase (Decrease) in Contract with Customer, Liability
CYTEK BIOSCIENCES, INC. (CTKB) reported Increase (Decrease) in Contract with Customer, Liability of $31.58 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-05
- CYTEK BIOSCIENCES, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was $15.11M, a 409.13% increase year-over-year.
- CYTEK BIOSCIENCES, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was $16.48M, a 9.08% increase year-over-year.
- CYTEK BIOSCIENCES, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was $44.84M, a 227.98% increase year-over-year.
- CYTEK BIOSCIENCES, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was -$597.00K, a 104.16% decline year-over-year.
- CYTEK BIOSCIENCES, INC. increase (decrease) in contract with customer, liability for fiscal 2024 was $50.63M, a 5.71% increase from fiscal 2023.
- CYTEK BIOSCIENCES, INC. increase (decrease) in contract with customer, liability for fiscal 2023 was $47.90M, a 38.99% increase from fiscal 2022.
- CYTEK BIOSCIENCES, INC. increase (decrease) in contract with customer, liability for fiscal 2022 was $34.46M, a 37.01% increase from fiscal 2021.
- CYTEK BIOSCIENCES, INC. increase (decrease) in contract with customer, liability for fiscal 2021 was $25.15M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $15.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $31.58M 10-Q · filed 2026-08-05 | $76.42M derived: sum of 3 quarters · filed 2026-08-05 | $75.82M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $16.48M 10-Q · filed 2026-05-07 | $61.31M derived: sum of 2 quarters · filed 2026-08-05 | $60.71M derived: sum of 3 quarters · filed 2026-08-05 | $63.68M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $44.84M derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-05 | $44.24M derived: sum of 2 quarters · filed 2026-08-05 | $47.20M derived: sum of 3 quarters · filed 2026-08-05 | $62.31M 10-Q · filed 2026-08-05 |
| 2025-09-30 | -$597.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $2.37M derived: sum of 2 quarters · filed 2025-11-05 | $17.48M 10-Q · filed 2025-11-05 | $31.14M derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-06-30 | $2.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $18.07M 10-Q · filed 2025-08-06 | $31.74M derived: sum of 3 quarters · filed 2026-02-26 | $46.09M derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-03-31 | $15.11M 10-Q · filed 2025-05-08 | $28.77M derived: sum of 2 quarters · filed 2026-02-26 | $43.12M derived: sum of 3 quarters · filed 2026-02-26 | $54.42M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-12-31 | $13.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $28.02M derived: sum of 2 quarters · filed 2026-02-26 | $39.32M derived: sum of 3 quarters · filed 2026-02-26 | $50.63M 10-K · filed 2026-02-26 |
| 2024-09-30 | $14.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $25.65M derived: sum of 2 quarters · filed 2024-11-07 | $36.96M 10-Q · filed 2024-11-07 | $44.22M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $11.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $22.61M 10-Q · filed 2024-08-06 | $29.87M derived: sum of 3 quarters · filed 2026-02-26 | |
| 2024-03-31 | $11.31M 10-Q · filed 2024-05-08 | $18.57M derived: sum of 2 quarters · filed 2026-02-26 | ||
| 2023-12-31 | $7.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $47.90M 10-K · filed 2026-02-26 | ||
| 2023-09-30 | $40.64M 10-Q · filed 2023-11-14 | |||
| 2022-12-31 | $34.46M 10-K · filed 2025-02-28 | |||
| 2021-12-31 | $25.15M 10-K · filed 2024-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |